---
document_datetime: 2025-12-02 04:54:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/abrysvo.html
document_name: abrysvo.html
version: success
processing_time: 0.113852
conversion_datetime: 2025-12-29 19:35:29.585774
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Abrysvo

[RSS](/en/individual-human-medicine.xml/67706)

##### Authorised

This medicine is authorised for use in the European Union

respiratory syncytial virus vaccine (bivalent, recombinant) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Abrysvo](#news-on)
- [More information on Abrysvo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Abrysvo is a vaccine for protecting against lower respiratory tract disease (LRTD; diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV) in people aged 18 years and older.

It is also used in pregnant women to protect their infants against LRTD from birth until they are 6 months of age.

Abrysvo contains versions of two proteins found on the surface of the virus called RSV subgroup A stabilised prefusion F and RSV subgroup B stabilised prefusion F.

Expand section

Collapse section

## How is Abrysvo used?

Abrysvo can only be obtained with a prescription and should be used according to official recommendations issued at national level by public health bodies.

The recommended dose is one single injection into the muscle of the upper arm. Pregnant women should receive the dose between weeks 24 and 36 of their pregnancy.

For more information about using Abrysvo, see the package leaflet or contact your doctor or pharmacist.

## How does Abrysvo work?

Abrysvo works by preparing the immune system (the body's natural defences) to defend against a LRTD caused by RSV. Abrysvo contains proteins from the surface of the RSV virus. When a person is given the vaccine, the immune system treats the viral proteins as 'foreign' and makes defences against them. If, later on, the vaccinated person comes into contact with the virus, the immune system will recognise the viral proteins and be prepared to attack it. This will help to protect against LRTD caused by the virus.

## What benefits of Abrysvo have been shown in studies?

In a study in over 34,000 adults aged 60 years and older, people who received Abrysvo had a 67% reduction in their risk of getting LRTD caused by RSV compared with those who had a dummy injection. Of the 16,306 adults who received the vaccine, 11 developed severe RSV-LRTD, defined as LRTD with at least two or more lower respiratory symptoms of RSV, compared with 33 adults out of the 16,308 who received the dummy injection. In addition, 2 of those who received Abrysvo developed three or more symptoms of RSV-LRTD compared with 14 adults who received the dummy injection.

A second study in pregnant women showed that Abrysvo reduced the risk of RSV-LRTD by 51% in infants born to vaccinated mothers compared with those whose mothers received a dummy injection. Of 3,495 infants born to mothers vaccinated with Abrysvo, 57 developed RSV-LRTD within the first 6 months after birth, compared with 117 out of the 3,480 infants born to mothers who had a dummy injection.

In a third study involving 681 adults aged from 18 to 59 years and at high risk of developing severe LRTD caused by RSV, the immune response triggered by Abrysvo one month after vaccination was at least as effective as that seen in adults aged 60 years and older.

## What are the risks associated with Abrysvo?

For the full list of side effects and restrictions with Abrysvo, see the package leaflet.

The majority of side effects with Abrysvo were mild to moderate and resolved within a few days of vaccination.

The most common side effects (which may affect more than 1 in 10 people) with Abrysvo in adults include tiredness, headache, pain at the vaccination site and myalgia (muscle pain).

The most common side effects (which may affect more than 1 in 10 people) with Abrysvo in pregnant women at 24 to 36 weeks of their pregnancy include pain at the vaccination site, headache and myalgia.

## Why is Abrysvo authorised in the EU?

Abrysvo was shown to be effective at preventing RSV-LRTD in adults as well as in infants born to vaccinated mothers for at least the first 6 months of life. There are no major safety concerns and the majority of side effects with Abrysvo were mild or moderate. The European Medicines Agency therefore decided that Abrysvo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Abrysvo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Abrysvo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Abrysvo are continuously monitored. Suspected side effects reported with Abrysvo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Abrysvo

Abrysvo received a marketing authorisation valid throughout the EU on 23 August 2023.

Abrysvo : EPAR - Medicine Overview

Reference Number: EMA/80045/2025

English (EN) (122.7 KB - PDF)

**First published:** 15/09/2023

**Last updated:** 11/04/2025

[View](/en/documents/overview/abrysvo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-640)

български (BG) (156.07 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/bg/documents/overview/abrysvo-epar-medicine-overview_bg.pdf)

español (ES) (122.61 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/es/documents/overview/abrysvo-epar-medicine-overview_es.pdf)

čeština (CS) (145.77 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/cs/documents/overview/abrysvo-epar-medicine-overview_cs.pdf)

dansk (DA) (123.25 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/da/documents/overview/abrysvo-epar-medicine-overview_da.pdf)

Deutsch (DE) (128.05 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/de/documents/overview/abrysvo-epar-medicine-overview_de.pdf)

eesti keel (ET) (120.89 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/et/documents/overview/abrysvo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (149.18 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/el/documents/overview/abrysvo-epar-medicine-overview_el.pdf)

français (FR) (124.22 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/fr/documents/overview/abrysvo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (146.54 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/hr/documents/overview/abrysvo-epar-medicine-overview_hr.pdf)

italiano (IT) (122.54 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/it/documents/overview/abrysvo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (161.5 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/lv/documents/overview/abrysvo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (152.35 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/lt/documents/overview/abrysvo-epar-medicine-overview_lt.pdf)

magyar (HU) (146.17 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/hu/documents/overview/abrysvo-epar-medicine-overview_hu.pdf)

Malti (MT) (154.07 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/mt/documents/overview/abrysvo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.45 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/nl/documents/overview/abrysvo-epar-medicine-overview_nl.pdf)

polski (PL) (150 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/pl/documents/overview/abrysvo-epar-medicine-overview_pl.pdf)

português (PT) (123.81 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/pt/documents/overview/abrysvo-epar-medicine-overview_pt.pdf)

română (RO) (151.78 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/ro/documents/overview/abrysvo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (145.3 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/sk/documents/overview/abrysvo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.58 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/sl/documents/overview/abrysvo-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.68 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/fi/documents/overview/abrysvo-epar-medicine-overview_fi.pdf)

svenska (SV) (121.84 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

11/04/2025

[View](/sv/documents/overview/abrysvo-epar-medicine-overview_sv.pdf)

Abrysvo : EPAR - Risk Management Plan

English (EN) (1.71 MB - PDF)

**First published:** 15/09/2023

**Last updated:** 02/06/2025

[View](/en/documents/rmp/abrysvo-epar-risk-management-plan_en.pdf)

## Product information

Abrysvo : EPAR - Product Information

English (EN) (507.73 KB - PDF)

**First published:** 15/09/2023

**Last updated:** 14/10/2025

[View](/en/documents/product-information/abrysvo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-557)

български (BG) (527.37 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/bg/documents/product-information/abrysvo-epar-product-information_bg.pdf)

español (ES) (522.41 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/es/documents/product-information/abrysvo-epar-product-information_es.pdf)

čeština (CS) (518.46 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/cs/documents/product-information/abrysvo-epar-product-information_cs.pdf)

dansk (DA) (509.65 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/da/documents/product-information/abrysvo-epar-product-information_da.pdf)

Deutsch (DE) (539.04 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/de/documents/product-information/abrysvo-epar-product-information_de.pdf)

eesti keel (ET) (515.3 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/et/documents/product-information/abrysvo-epar-product-information_et.pdf)

ελληνικά (EL) (539.7 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/el/documents/product-information/abrysvo-epar-product-information_el.pdf)

français (FR) (520.67 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/fr/documents/product-information/abrysvo-epar-product-information_fr.pdf)

hrvatski (HR) (515.66 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/hr/documents/product-information/abrysvo-epar-product-information_hr.pdf)

íslenska (IS) (516.56 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/is/documents/product-information/abrysvo-epar-product-information_is.pdf)

italiano (IT) (530.6 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/it/documents/product-information/abrysvo-epar-product-information_it.pdf)

latviešu valoda (LV) (509.14 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/lv/documents/product-information/abrysvo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (505.97 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/lt/documents/product-information/abrysvo-epar-product-information_lt.pdf)

magyar (HU) (517.74 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/hu/documents/product-information/abrysvo-epar-product-information_hu.pdf)

Malti (MT) (562.04 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/mt/documents/product-information/abrysvo-epar-product-information_mt.pdf)

Nederlands (NL) (511.19 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/nl/documents/product-information/abrysvo-epar-product-information_nl.pdf)

norsk (NO) (517.7 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/no/documents/product-information/abrysvo-epar-product-information_no.pdf)

polski (PL) (521.04 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/pl/documents/product-information/abrysvo-epar-product-information_pl.pdf)

português (PT) (521.69 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/pt/documents/product-information/abrysvo-epar-product-information_pt.pdf)

română (RO) (511.89 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/ro/documents/product-information/abrysvo-epar-product-information_ro.pdf)

slovenčina (SK) (529.35 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/sk/documents/product-information/abrysvo-epar-product-information_sk.pdf)

slovenščina (SL) (503.73 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/sl/documents/product-information/abrysvo-epar-product-information_sl.pdf)

Suomi (FI) (475.88 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/fi/documents/product-information/abrysvo-epar-product-information_fi.pdf)

svenska (SV) (464.57 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

14/10/2025

[View](/sv/documents/product-information/abrysvo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000280927 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Abrysvo : EPAR - All authorised presentations

English (EN) (40.31 KB - PDF)

**First published:** 15/09/2023

**Last updated:** 18/07/2024

[View](/en/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-455)

български (BG) (41.72 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/bg/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_bg.pdf)

español (ES) (37.77 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/es/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/cs/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.6 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/da/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.88 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/de/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35.93 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/et/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.44 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/el/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_el.pdf)

français (FR) (37.28 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/fr/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.3 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/hr/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.64 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/is/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/it/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.85 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/lv/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (41.19 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/lt/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (37.99 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/hu/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.89 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/mt/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (39.71 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/nl/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (39.1 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/no/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.52 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/pl/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.11 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/pt/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.3 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/ro/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (40.16 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/sk/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.77 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/sl/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.97 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/fi/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.04 KB - PDF)

**First published:**

15/09/2023

**Last updated:**

18/07/2024

[View](/sv/documents/all-authorised-presentations/abrysvo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Abrysvo Active substance

- respiratory Syncytial Virus, subgroup A, stabilized prefusion F protein 847A
- respiratory syncytial virus, subgroup B, stabilized prefusion F protein 847B

International non-proprietary name (INN) or common name respiratory syncytial virus vaccine (bivalent, recombinant) Therapeutic area (MeSH) Respiratory Syncytial Virus Infections Anatomical therapeutic chemical (ATC) code J07BX05

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Abrysvo is indicated for:

- Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy.
- Active immunisation of individuals 18 years of age and older for the prevention of lower respiratory tract disease caused by RSV.

The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/006027

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 20/07/2023 Marketing authorisation issued 23/08/2023 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Abrysvo : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (177.09 KB - PDF)

**First published:** 20/08/2025

**Last updated:** 14/10/2025

[View](/en/documents/procedural-steps-after/abrysvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Abrysvo : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (184.87 KB - PDF)

**First published:** 20/03/2024

**Last updated:** 20/08/2025

[View](/en/documents/procedural-steps-after/abrysvo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Abrysvo-H-C-006027-II-0007 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/109450/2025

English (EN) (2.98 MB - PDF)

**First published:** 15/04/2025

[View](/en/documents/variation-report/abrysvo-h-c-006027-ii-0007-epar-assessment-report-variation_en.pdf)

Abrysvo-H-C-006027-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/486812/2024

English (EN) (1.17 MB - PDF)

**First published:** 28/11/2024

[View](/en/documents/variation-report/abrysvo-h-c-006027-p46-006-epar-assessment-report_en.pdf)

Abrysvo-H-C-006027-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/295348/2024

English (EN) (1.71 MB - PDF)

**First published:** 05/09/2024

[View](/en/documents/variation-report/abrysvo-h-c-006027-p46-005-epar-assessment-report_en.pdf)

Abrysvo-H-C-PSUSA-00000102-202311 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/394691/2024

English (EN) (98.77 KB - PDF)

**First published:** 05/09/2024

[View](/en/documents/scientific-conclusion/abrysvo-h-c-psusa-00000102-202311-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Abrysvo : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/351226/2023

English (EN) (6.72 MB - PDF)

**First published:** 15/09/2023

[View](/en/documents/assessment-report/abrysvo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Abrysvo

Adopted

Reference Number: EMA/CHMP/327338/2023

English (EN) (117.29 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-abrysvo_en.pdf)

#### News on Abrysvo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2025) 28/02/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

[First RSV vaccine to protect infants up to 6 months of age and older adults](/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults) 21/07/2023

#### More information on Abrysvo

- [A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK (C3671038) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000400)
- [A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK (C3671026) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000399)
- [Evaluating the benefits of RSV maternal vaccination using a Scottish National Dataset. (BORLAND) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000706)
- [A Post-Authorization Safety Study of Guillain-Barré Syndrome (GBS) Following ABRYSVOTM Among Older Adults in the United States (C3671031) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000753)
- [Effectiveness and immunogenicity of respiratory syncytial virus vaccine (RSVpreF from Pfizer) for pregnant persons: A living systematic review and meta-analysis - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000713)
- [id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000035)
- [Observational Cohort Study Evaluating Real-World ABRYSVO Vaccine Effectiveness and Impact Against Medically-Attended RSV-related and All-Cause Outcomes Among Infants Born to Individuals Vaccinated During Pregnancy - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000295)
- [A Post-Authorization Safety Study of Atrial Fibrillation Following Respiratory Syncytial Virus Vaccine (ABRYSVOTM) Among Older Adults in the Veterans Affairs Health System (C3671037) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000290)
- [Epidemiology of Guillain-Barré Syndrome and Risk Associated with Exposure to ABRYSVO Among Vaccinees 18-59 Years of Age in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000629)
- [A Post-Marketing Near Real-Time Safety Surveillance of Respiratory Syncytial Virus Vaccine for Guillain-Barre Syndrome (GBS) among Older Adults in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000267)
- [STudy of Real world vaccinE Effectiveness of maTernal RSVpreF vaccinatiON against respiratory syncytial virus (RSV) in hospitalised infants in Australia (STREETON) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000598)
- [A Rapid Surveillance and Cohort Post-Marketing Safety Study to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy in the United States (C3671027) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000115)
- [A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000480)
- [A Post-Marketing Safety Study using a Pregnancy Registry to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy (C3671041) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000179)
- [Retrospective Study Evaluating ABRYSVO® Vaccine Effectiveness Against Severe Lower Respiratory Tract Disease in Older Adults - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000460)
- [Effectiveness of ABRYSVO® maternal respiratory syncytial virus (RSV) vaccine against RSV in infants in Western Pennsylvania (CASSATT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000389)
- [Real World Impact and Effectiveness of ABRYSVO Vaccination During Pregnancy Against RSV Illness in Infants (BERNI) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000224)

**This page was last updated on** 14/10/2025

## Share this page

[Back to top](#main-content)